• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MSLN 基因产物(间皮素和巨核细胞促进因子)在胸腔积液和血清中作为间皮瘤生物标志物的诊断准确性比较。

Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

机构信息

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia and Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia.

出版信息

Dis Markers. 2013;35(2):119-27. doi: 10.1155/2013/874212. Epub 2013 Aug 6.

DOI:10.1155/2013/874212
PMID:24167356
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3774973/
Abstract

The MSLN gene products, soluble mesothelin and megakaryocyte potentiating factor (MPF), are being investigated as biomarkers for the asbestos-related cancer malignant mesothelioma (MM). Pleural fluid biomarkers of MM can be elevated when serum levels remain normal. The aim of this study was to determine if this was true for MPF and to compare levels of mesothelin. Biomarker concentrations were compared in 66 MM patients, 39 patients with other malignancies, 37 with benign disease, 18 asbestos-exposed healthy individuals, and 53 patients with chronic kidney disease. In pleural effusions, MPF and soluble mesothelin concentrations were both significantly elevated in MM patients relative to controls. No significant difference between the area under the receiver operator curve (AUC) for MPF (0.945 ± 0.02) and mesothelin (0.928 ± 0.03) when distinguishing MM from all other causes of effusion was observed. MPF and mesothelin serum concentrations were highly correlated and of equivalent diagnostic accuracy with AUCs of 0.813 ± 0.04 and 0.829 ± 0.03, respectively. Serum levels of both markers increased with decreasing kidney function. In conclusion, MPF is elevated in the pleural effusions of MM patients similar to that of mesothelin. Mesothelin and MPF convey equivalent diagnostic information for distinguishing MM from other diseases in pleural effusions as well as serum.

摘要

MSLN 基因产物,可溶性间皮素和巨核细胞促成熟因子(MPF),正被作为与石棉相关的癌症恶性间皮瘤(MM)的生物标志物进行研究。当血清水平保持正常时,胸腔液中的 MM 生物标志物可能会升高。本研究的目的是确定 MPF 是否也是如此,并比较间皮素的水平。在 66 名 MM 患者、39 名其他恶性肿瘤患者、37 名良性疾病患者、18 名接触石棉的健康个体和 53 名慢性肾病患者中比较了生物标志物浓度。在胸腔积液中,与对照组相比,MM 患者的 MPF 和可溶性间皮素浓度均显著升高。在区分 MM 与所有其他胸腔积液病因时,MPF(0.945±0.02)和间皮素(0.928±0.03)的曲线下面积(AUC)之间没有显著差异。MPF 和间皮素的血清浓度高度相关,诊断准确性相当,AUC 分别为 0.813±0.04 和 0.829±0.03。两种标志物的血清水平均随肾功能下降而升高。总之,MPF 在 MM 患者的胸腔积液中升高,与间皮素相似。间皮素和 MPF 在区分胸腔积液中的 MM 与其他疾病以及血清中具有相当的诊断信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7aaa/3774973/489e90895495/DM35-02-874212.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7aaa/3774973/1e4c4ea2d3ee/DM35-02-874212.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7aaa/3774973/9646f6bacd42/DM35-02-874212.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7aaa/3774973/489e90895495/DM35-02-874212.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7aaa/3774973/1e4c4ea2d3ee/DM35-02-874212.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7aaa/3774973/9646f6bacd42/DM35-02-874212.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7aaa/3774973/489e90895495/DM35-02-874212.003.jpg

相似文献

1
Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.MSLN 基因产物(间皮素和巨核细胞促进因子)在胸腔积液和血清中作为间皮瘤生物标志物的诊断准确性比较。
Dis Markers. 2013;35(2):119-27. doi: 10.1155/2013/874212. Epub 2013 Aug 6.
2
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.骨桥蛋白、巨核细胞增强因子和间皮素蛋白作为恶性间皮瘤患者血清标志物的比较
J Thorac Oncol. 2008 Aug;3(8):851-7. doi: 10.1097/JTO.0b013e318180477b.
3
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.巨核细胞增强因子作为恶性胸膜间皮瘤的肿瘤标志物:与间皮素相比的评估
Lung Cancer. 2008 Oct;62(1):45-54. doi: 10.1016/j.lungcan.2008.02.012. Epub 2008 Apr 3.
4
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.可溶性间皮素和巨核细胞促进因子在间皮瘤中的诊断性能。
Am J Respir Crit Care Med. 2010 Mar 15;181(6):620-5. doi: 10.1164/rccm.200907-1020OC. Epub 2010 Jan 14.
5
Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.接触天然石棉的间皮瘤和胸膜斑患者及健康受试者的血清生物标志物。
Lung. 2014 Feb;192(1):197-203. doi: 10.1007/s00408-013-9526-9. Epub 2013 Oct 30.
6
A recombinant polypeptide of the megakaryocyte potentiating factor is a potential biomarker in plasma for the detection of mesothelioma.巨核细胞增强因子的重组多肽是血浆中用于检测间皮瘤的潜在生物标志物。
Biochem Biophys Res Commun. 2017 Apr 29;486(2):526-532. doi: 10.1016/j.bbrc.2017.03.077. Epub 2017 Mar 19.
7
Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.间皮素、钙视网膜蛋白和巨核细胞增强因子作为恶性胸膜间皮瘤的生物标志物。
Lung. 2019 Oct;197(5):641-649. doi: 10.1007/s00408-019-00244-1. Epub 2019 Jul 2.
8
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.间皮瘤血清和胸腔积液中可溶性间皮素相关肽水平升高。
Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272. doi: 10.1016/j.athoracsur.2007.07.042.
9
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.中期因子是恶性间皮瘤一种潜在的新型标志物,其预后和诊断价值与间皮素不同。
BMC Cancer. 2017 Mar 23;17(1):212. doi: 10.1186/s12885-017-3209-5.
10
Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.联合检测间皮素和 CEA 可显著提高恶性胸膜间皮瘤、良性石棉肺和肺癌的鉴别诊断能力。
J Thorac Oncol. 2013 Jul;8(7):947-51. doi: 10.1097/JTO.0b013e31828f696b.

引用本文的文献

1
Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.胸膜间皮瘤:血液和胸膜生物标志物的进展
J Clin Med. 2023 Nov 9;12(22):7006. doi: 10.3390/jcm12227006.
2
Diagnostic and Prognostic Value of Three microRNAs in Environmental Asbestiform Fibers-Associated Malignant Mesothelioma.三种微小RNA在环境石棉样纤维相关恶性间皮瘤中的诊断和预后价值
J Pers Med. 2021 Nov 15;11(11):1205. doi: 10.3390/jpm11111205.
3
Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis.

本文引用的文献

1
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.胸腔积液细胞学检查可诊断恶性胸膜间皮瘤:20 年回顾性分析结果。
Pathology. 2013 Jan;45(1):44-8. doi: 10.1097/PAT.0b013e32835bc848.
2
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.可溶性间皮素、巨核细胞增强因子和骨桥蛋白作为间皮瘤患者反应和预后的标志物。
J Thorac Oncol. 2011 Nov;6(11):1930-7. doi: 10.1097/JTO.0b013e3182272294.
3
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
诊断生物标志物在恶性胸膜间皮瘤中的临床应用:系统评价和荟萃分析。
Eur Respir Rev. 2021 Nov 17;30(162). doi: 10.1183/16000617.0057-2021. Print 2021 Dec 31.
4
Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.正中靶心:间皮素作为恶性胸膜间皮瘤生物标志物和治疗靶点的作用
Cancers (Basel). 2021 Aug 4;13(16):3932. doi: 10.3390/cancers13163932.
5
Update of , and fluoro-edenite effects on malignant mesothelioma: A systematic review (Review).氟绿脆云母、氟羟硅钠石及氟钠云母对恶性间皮瘤影响的最新研究:一项系统综述(综述)
Biomed Rep. 2020 Dec;13(6):60. doi: 10.3892/br.2020.1367. Epub 2020 Oct 15.
6
Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.间皮素、钙视网膜蛋白和巨核细胞增强因子作为恶性胸膜间皮瘤的生物标志物。
Lung. 2019 Oct;197(5):641-649. doi: 10.1007/s00408-019-00244-1. Epub 2019 Jul 2.
7
Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma.巨核细胞增强因子作为恶性间皮瘤治疗的预测性生物标志物
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00282. Epub 2018 May 11.
8
Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.恶性胸膜间皮瘤中的过表达基因:对临床管理的意义。
J Thorac Dis. 2018 Jan;10(Suppl 2):S369-S382. doi: 10.21037/jtd.2017.10.158.
9
Biomarkers in the prevention and follow-up of workers exposed to asbestos.生物标志物在石棉暴露工人的预防和随访中的应用
J Thorac Dis. 2018 Jan;10(Suppl 2):S360-S368. doi: 10.21037/jtd.2017.12.17.
10
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?恶性间皮瘤早期诊断的生物标志物:我们还需要另一次登月计划式的努力吗?
Oncotarget. 2017 May 17;8(32):53751-53762. doi: 10.18632/oncotarget.17910. eCollection 2017 Aug 8.
可溶性间皮素和巨核细胞促进因子对临床变量的诊断和预后价值的影响。
Chest. 2012 Feb;141(2):477-484. doi: 10.1378/chest.11-0129. Epub 2011 Jul 7.
4
Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.对暴露于石棉的个体中的间皮瘤血清生物标志物进行连续测量:一项前瞻性纵向队列研究。
J Thorac Oncol. 2011 May;6(5):889-95. doi: 10.1097/JTO.0b013e31820db377.
5
Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.间皮素与肾功能——关系分析及对间皮瘤筛查的意义。
Lung Cancer. 2011 Sep;73(3):320-4. doi: 10.1016/j.lungcan.2011.01.011. Epub 2011 Feb 18.
6
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.可溶性间皮素和巨核细胞促进因子在间皮瘤中的诊断性能。
Am J Respir Crit Care Med. 2010 Mar 15;181(6):620-5. doi: 10.1164/rccm.200907-1020OC. Epub 2010 Jan 14.
7
Serum and pleural fluid biomarkers for mesothelioma.间皮瘤的血清和胸腔积液生物标志物
Curr Opin Pulm Med. 2009 Jul;15(4):366-70. doi: 10.1097/MCP.0b013e32832b98eb.
8
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.未确诊胸腔积液中胸水间皮素的临床影响及可靠性
Am J Respir Crit Care Med. 2009 Sep 1;180(5):437-44. doi: 10.1164/rccm.200811-1729OC. Epub 2009 Mar 19.
9
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.骨桥蛋白、巨核细胞增强因子和间皮素蛋白作为恶性间皮瘤患者血清标志物的比较
J Thorac Oncol. 2008 Aug;3(8):851-7. doi: 10.1097/JTO.0b013e318180477b.
10
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.巨核细胞增强因子作为恶性胸膜间皮瘤的肿瘤标志物:与间皮素相比的评估
Lung Cancer. 2008 Oct;62(1):45-54. doi: 10.1016/j.lungcan.2008.02.012. Epub 2008 Apr 3.